MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin

Nunu Huang1,2, Jiangbin Wu1,2,*, Wei Qiu2,3, Qing Lyu1,2, Jie He2, Weidong Xie2, Naihan Xu2,*, and Yaou Zhang2,*

1School of Life Sciences; Tsinghua University; Beijing, China; 2Key Lab in Healthy Science and Technology; Division of Life Science; The Graduate School at Shenzhen; Tsinghua University; Shenzhen, China; 3The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Lab of Chemical Biology; The Graduate School at Shenzhen; Tsinghua University; Shenzhen, China

Both authors contributed equally to this work.

**Keywords:** autophagy, Camptothecin, cell proliferation, microRNA, mTOR, Rictor

**Abbreviations:** BAFA1, bafilomycin A1; CPT, Camptothecin; miRNA, microRNA; LC3, microtubule-associated protein 1 light chain 3; mTOR, mechanistic target of rapamycin; Rictor, Rptor independent companion of mTOR complex 2; MUT, mutated; UTR, untranslated region; NC, negative control.

It has been reported that persistent or excessive autophagy promotes cancer cell death during chemotherapy, either by enhancing the induction of apoptosis or mediating autophagic cell death. Here, we show that miR-15a and miR-16 are potent inducers of autophagy. Rictor, a component of mTORC2 complex, is directly targeted by miR-15a/16. Overexpression of miR-15a/16 or depletion of endogenous Rictor attenuates the phosphorylation of mTORC1 and p70S6K, inhibits cell proliferation and G1/S cell cycle transition in human cervical carcinoma HeLa cells. Moreover, miR-15a/16 dramatically enhances anticancer drug camptothecin (CPT)-induced autophagy and apoptotic cell death in HeLa cells. Collectively, these data demonstrate that miR-15a/16 induced autophagy contribute partly to their inhibition of cell proliferation and enhanced chemotherapeutic efficacy of CPT.

**Introduction**

Autophagy is an evolutionarily conserved cellular catabolic process, by which damaged or excessive organelles and cytoplasmic proteins are degraded through lysosome degradation system.1 Recently, autophagy has been proposed to play important roles in many physiological and pathological processes, such as cell proliferation, differentiation and metabolism.2–5 The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis, including autophagy.6 It is well established that activation of rapamycin-sensitive mTORC1 inhibits autophagosome formation through phosphorylating and repressing Ulk1 kinase activity.7 mTORC1 also indirectly regulates autophagy by controlling lysosome biogenesis through phosphorylation of transcription factor EB (TFEB), which drives the transcription of several lysosome- and autophagy-specific genes.8 Unlike mTORC1, much less is known about rapamycin-insensitive mTORC2 pathway. After being activated by growth factors, mTORC2 regulates cell growth and proliferation via phosphorylation of Akt at Ser473 and SGK1.9 Activation of Akt and SGK1 results in phosphorylation and nuclear export inactivation of the transcription factor FoxO3a,9,10 which regulates the expression of autophagy-related genes, such as LC3 and BNIP3.11,12 In this manner, mTORC2 also acts as a negative regulator of autophagy.

MicroRNAs (miRNAs) are a class of noncoding RNA that negatively regulate gene expression through binding to the 3′ untranslated region (3′UTR).13,14 MiRNAs are important regulators in various fundamental biological and pathological processes, such as cell proliferation, apoptosis, differentiation, metabolism, and cancer, as well as autophagy.15–20 MiRNAs have recently been identified as important regulators of autophagy.19 Some miRNAs suppress autophagic activity via targeting autophagy-related proteins (ATGs) under stress conditions. It has been shown that miR-20a impedes autophagy through Atg16L1 during hypoxia induced osteoclast differentiation,21 while miR-181a inhibits starvation and rapamycin induced autophagy through Atg5.22 Some miRNAs promote autophagy...
by repressing important upstream signals of autophagy pathway. For example, hypoxia induced miR-155 promotes autophagic activity through targeting Rheb and other component in mTOR signaling.\(^{23,24}\) miR-34a inhibits autophagy and enhances chemotherapy-induced apoptosis in the retinoblastoma cell through HMGB1.\(^{25}\)

The miR-15a/107 group of miRNA contains a series of miRNAs, including miR-15a, miR-15b, miR-16, miR-103 and miR-107 family. MiR-15a and miR-16 form 2 different clusters in mammals and these 2 miRNAs are found to be frequently deleted or downregulated in many types of cancers, including chronic lymphocytic leukemia (CLL), colorectal cancer, squamous-cell carcinoma, ovarian cancer and prostate cancer.\(^{26}\) As tumor suppressors, miR-15a and miR-16 were shown to inhibit cancer cell proliferation by targeting various cyclins and CDKs and induce apoptosis through down-regulating the anti-apoptotic gene Bcl-2.\(^{27–29}\) In the present study, we report miR-15a and miR-16 directly target Rictor, an important component in mTORC2 pathway. Overexpression of miR-15a/16 or knockdown Rictor downregulate mTORC1/p70S6K, increase autophagic activity. In addition, miR-15a/16 significantly enhances antitumor drug CPT-induced apoptotic cell death through excessive autophagy.

**Results**

MiR-15a/16 increases autophagic activity

To elucidate the effects of miR-15a and miR-16 on autophagy, we performed LC3 puncta formation and LC3 conversion assays. HeLa cells stably expressing GFP-LC3 fusion protein were transiently transfected with miR-15a or miR-16 mimics. GFP-LC3 puncta formation was visualized by confocal microscope. As shown in Figure 1A, there was a significant increase of GFP-LC3 puncta in cells transfected with miR-15a or miR-16 compared with the negative control (NC). Quantification of GFP-LC3 dots in each cell confirmed that autophagosomes accumulated when miR-15a and miR-16 were over-expressed (Fig. 1B).

We then detected the conversion of LC3-I to LC3-II and p62 expression using western blot. Consistent with the results from the GFP-LC3 puncta assay, there was a significant increase of lipidated LC3-II in cells transfected with miR-15a or miR-16 (Fig. 1C). p62/SQSTM1 is a selective substrate for autophagy-lysosome degradation, so total p62 protein levels reflect autophagic activity. Indeed, overexpression of miR-15a and miR-16 resulted in reduced p62 protein levels (Fig. 1C). To test whether the increase in autophagosomes is due to increased autophagy activity or a block in downstream...
degradation, we performed an autophagic flux assay. Bafilomycin A1 (Baf A1) is a lysosomotropic reagent that blocks autophagosome degradation. As we expected, Baf A1 treatment caused elevated levels of LC3-II in the NC, miR-15a and miR-16 transfected cells (Fig. 1D and E). In addition, p62 protein levels also increased upon Baf A1 treatment in miR-15a and miR-16 transfected cells (Fig. 1D and F). Therefore, we conclude that miR-15a and miR-16 increase autophagic activity.

**Inhibition of endogenous miR-15a and miR-16 repress autophagic activity.**

To further identify the connection between miR-15a, miR-16 and autophagy, we inhibited endogenous miR-15a and miR-16 expression and repeated the above assays. We used a single strand miRNA inhibitor (Ant-miR-15a and Ant-miR-16) to block endogenous miR-15a and miR-16 expression (Fig. 2A). GFP-LC3 puncta accumulation was suppressed when endogenous miR-15a and miR-16 were inhibited (Fig. 2B and C). A Western blot of LC3 conversion and p62 expression also showed that inhibition of miR-15a or miR-16 resulted in a decrease in LC3-II conversion and an increase in p62 expression (Fig. 2D). These results demonstrate the relevance of endogenous miR-15a and miR-16 with autophagy.

**Rictor is a direct target of miR-15a and miR-16.**

Having confirmed miR-15a and miR-16 function in the regulation of autophagy, we employed the miRNA prediction algorithm, Findtar and TargetScan, to clarify potential targets of miR-15a and miR-16. Both of the algorithms predicted Rictor as a potential target of miR-15a and miR-16 (Fig. 3A). We measured Rictor protein expression levels using immunoblot and results showed that Rictor protein expression was significantly lower when miR-15a and miR-16 were overexpressed and protein levels significantly increased when endogenous miR-15a and miR-16 were inhibited (Fig. 3B).

In order to confirm the direct binding of miR-15a and miR-16 to 3’UTR of Rictor mRNA, the 3’UTR fragments containing wild-type (WT) or mutated (MUT) seed regions of the miR-15a and miR-16 targets were cloned into a dual-luciferase reporter vector (Fig. 3A). The WT reporter vector exhibited a significant reduction of luciferase activity when co-transfected with miR-15a and miR-16 compared to NC. In contrast, the seed region mutation vector abrogated this inhibitory effect of miR-15a and

---

**Figure 2.** Inhibition of endogenous miR-15a and miR-16 repress autophagic activity. (A) Blockage of endogenous miR-15a or miR-16 expression by transfection of single strand ant-miRNA. (B) Inhibition of endogenous miR-15a or miR-16 inhibits GFP-LC3 puncta formation. HeLa cells transfected with ant-miR-15a, ant-miR-16 or control (ant-NC) were fixed at 48 h after transfection. Representative images were captured by confocal microscope. Scale bar, 10 μm. (C) Quantitative analysis of GFP-LC3 puncta per cell. At least 200 cells were examined in each experimental group. Data shown are means ± SD of three independent experiments. **P < 0.01. (D) HeLa cells were transfected with ant-miR-15a, ant-miR-16 or ant-NC. Western blotting was performed to analyze the status of LC3, p62, and GAPDH.
miR-16 (Fig. 3C). Therefore, miR-15a and miR-16 suppress Rictor expression through direct binding to its 3’UTR.

Knockdown of Rictor has effects similar to miR-15a or miR-16

After we identified that Rictor is a real target of miR-15a and miR-16, we wanted to test whether knockdown of Rictor has a similar effect on autophagy. We used Rictor siRNA to knock down its endogenous expression and explore its function on LC3 conversion or p62 protein degradation. As shown in Figure 3D, Rictor siRNA has the effect of increasing LC3 conversion and decreasing p62 protein levels, similar to miR-15a and miR-16. Therefore, miR-15a and miR-16 may induce autophagy by suppressing Rictor expression.

It has previously been reported that mTORC2 can activate mTORC1 through Akt phosphorylation.32 Consistent with previous descriptions, mTORC1 activity was downregulated when we knocked down Rictor with siRNA. Phosphorylation of mTOR and downstream p70S6K were reduced in Rictor knocked-down cells. Overexpression of miR-15a or miR-16 had an effect on mTORC1 and p70S6K activity, similar to Rictor siRNA (Fig. 4A). These data cumulatively reveal that miR-15a and miR-16 have an effect on autophagy and mTORC1 activity that is similar to Rictor siRNA.

MiR-15a and miR-16 inhibit cell growth partly through autophagy

In order to test whether miR-15a and miR-16 exert their cell inhibitory function through autophagy, we performed MTT and flow cytometry analysis. As shown in Figure 4B, the MTT assay revealed that there was a significant reduction in cell growth at 48h in cells transfected with miR-15a, miR-16 or Rictor siRNA. A flow cytometry assay also showed G1 arrest in cells overexpressing miR-15a/16, as well as in cells with Rictor knockdown (Fig. 4C). Atg7 is an E1-like enzyme and required for covalent conjugation of Atg12 to Atg5. Atg7 is an essential gene for autophagy, so we used Atg7 siRNA to block autophagy. Our results demonstrated that blocking autophagic activity abolished the G1/S arrest by miR-15a/16 or Rictor siRNA (Fig. 4D). The cell proliferation assay also showed that depletion of Atg7 partly restored the inhibitory effect of miR-15a/16 and Rictor siRNA on cell proliferation (Fig. 4B). These indicate that there is a potential link between miR-15a and miR-16 induced autophagy and inhibition of cell proliferation.

MiR-15a and miR-16 enhance chemotherapeutic efficacy of Camptothecin

Camptothecin (CPT) is an anti-cancer drug used in cancer chemotherapy. At concentrations of both 5uM and 10uM, treatment with CPT dramatically induced autophagy and apoptotic cell death in HeLa cells, as revealed by LC3-II conversion, p62 degradation, cleavage of PARP and caspase-3 (Fig. 5A). Interestingly, overexpression of miR-15a or miR-16 significantly increased CPT-induced autophagic activity, whereas knockdown endogenous miR-15a/16 produced the opposite effects (Fig. 5B). Then we tested whether miR-15a and miR-16 would enhance the anti-cancer efficacy of CPT. Cells transfected with miR-15a or miR-16 exhibited more
rigorously decrease in the cell proliferation assay (Fig. 5C). Immunoblotting results also confirmed that CPT induced apoptosis was greatly enhanced by miR-15a or miR-16 compared with NC while knockdown endogenous miR-15a and miR-16 decreased CPT induced apoptosis as determined by cleaved PARP1 and caspase-3 (Fig. 5D). Moreover, flow cytometry assay showed that miR-15a and miR-16 transfection led to more apoptotic cells than CPT only (Fig. 5E and F). Collectively, these data support the notion that miR-15a and miR-16 down-regulate cell proliferation partly through modulation of autophagy and enhance chemotherapeutic efficacy of the anticancer drug CPT.

**Discussion**

MiRNAs are important regulators in various biological processes by targeting genes in different signaling pathways. MiR-15a and miR-16 were reported as tumor suppressors and inhibited cancer cell proliferation.26 MiR-15a and miR-16 are frequently deleted or down-regulated in cancer, especially in chronic lymphocytic leukemia (CLL), overexpression of miR-15a and miR-16 suppresses cancer cell proliferation.23 In this study, we discovered that miR-15a and miR-16 inhibit cell proliferation partly through autophagy induction. MiR-15a/16 mediated repression of Rictor lead to downregualtion of mTORC1/p70S6K, induction of autophagy and inhibition of cell proliferation.

mTOR plays a central role in nutrient sensing and homeostasis of cellular biosynthesis and degradation. mTOR forms 2 complexes, designated as mTORC1 and mTORC2, respectively. Rictor is an essential component of mTORC2 and is activated by growth factors.34,35 Once mTORC2 is activated, it induces cell proliferation through the phosphorylation of the AGC family of kinases, such as Akt, SGK and PKC.9 Through phosphorylation of Akt, mTORC2 can positively regulate the activity of mTORC1.9,32 It would be reasonable to speculate that mTORC2 acts as a negative regulator of autophagy. Consistent with this view, inhibition of mTORC2 activity induces autophagy and muscle atrophy through activation of FoxO3, a transcription factor downstream of Akt that induces expression of many autophagy-related genes.11,12 However, mTORC2 has also been reported as a positive regulator of autophagy through mTORC2-Ypk signaling during amino acid starvation.36,37 Therefore, the function of mTORC2 in autophagy regulation is dependent on cell context. Our results indicate that mTORC2 acts as a negative regulator and knockdown of Rictor induces autophagy.

Chemotherapy and radiotherapy play important roles in current cancer therapies and create an interplay between autophagy and cancer therapy.38 Combination chemotherapy is widely used to treat cancer and is more effective than single chemotherapy because of resistance to single chemical treatments.39 Several lines of evidence implicates a paradoxical role of autophagy following anticancer treatments. Autophagy induction can increase or decrease anticancer drug efficacy. On the one hand, autophagy is activated as a pro-survival mechanism in some cancer cells during chemotherapy. Inhibition of autophagy can re-sensitize drug resistant cancer cells and augment cytotoxicity of chemotherapeutic agents. On the other hand, persistent or excessive
autophagy promotes cancer cell death during chemotherapy, either by enhancing the induction of apoptosis or mediating autophagic cell death.\(^{40}\) Several lines of evidence suggest that miRNA sensitizes cancer cells to chemotherapeutic drugs through the regulation of autophagy signaling.\(^{41-44}\) It has been reported that miR-30a suppresses Beclin 1-mediated autophagy and sensitizes tumor cells to cisplatinum.\(^{45}\) However, miR-21 downregulation causes enhanced autophagic activity and increased chemosensitivity to etoposide or doxorubicin in K562 and KYO-1 cells, and this chemosensitivity was reverted by pre-treating cells with autophagy inhibitor 3-MA.\(^{46}\) Inhibition of miR-25 leads to autophagic cell death and increases chemosensitivity to isoliquiritigenin in MCF-7/ADR cells.\(^{47}\) Considering the paradoxical role of autophagy in cancer therapy, recognizing functional autophagy status in tumors will be required to direct the appropriate therapy.

Taken together, our study suggests that Rictor is one of the direct targets of miR-15a and miR-16 and this accounts for its function in autophagy induction. The connection between Rictor and autophagy contributes partly to the inhibition of cell proliferation caused by miR-15a and miR-16. In addition, further, miR-15a and miR-16-mediated autophagy induction increases the chemosensitivity of HeLa cells to CPT. Both miR-15a and miR-16 might be potential candidates for combination therapy of miRNA and CPT or other chemotherapeutic agents.

Materials and Methods

Cell culture
HeLa (human cervical cancer, ATCC, CCL-2) cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, 12800–017) supplemented with 10% fetal bovine serum (FBS, PAA, A15–101), 10 U/mL penicillin-streptomycine (Gibco/Invi- trogen, 15140–122) at 37\(^\circ\)C in a humidified 5% CO\(_2\) incubator.

Target prediction
Two conventional online programs: Targetscan (http://www.targetscan.org) and Findtar (http://bio.sz.tsinghua.edu.cn) were used to predict the targets and precise binding sites of MIR15a and MIR16.

MiRNA and siRNA transfection
All miRNA mimics, miRNA inhibitors and siRNAs were purchased from Shanghai GenePharma Co. Ltd. The sequences of siRNAs were used as follows:
siRictor-1: 5'-GCAGCCUUGAACUGUUAATT-3', 5'-UUAACAGUCAAGGCUUGCTT-3'
siRictor-2: 5'-CUUGUAGAAUCGUAUCUUTT-3', 5'-AAGAUACGUAUCUCAAGTT-3'

Figure 5. MiR-15a and miR-16 enhance chemotherapeutic efficacy of Camptothecin. (A) Camptothecin (CPT) induced LC3 conversion, p62 degradation, and cleavage of caspase 3 and PARP. (B) Transfection of miR-15a or miR-16 increased CPT-induced autophagy and inhibition of endogenous miR-15a or miR-16 had the opposite effects on CPT-induced autophagy. Image J densitometric analysis of LC3-II/GAPDH and p62/GAPDH was shown. (C) Cell viability assay of HeLa cells transfected with miR-15a, miR-16 or Rictor siRNA in DMSO or CPT treated cells. Data shown are means ± SD of three independent experiments, \(*P < 0.01\), student 2-tailed t test. (D) Western blot analysis of cleaved PARP1 and caspase 3 in HeLa cells transfected with miR-15a, miR-16, Rictor siRNA, NC or anti-miR-15a, anti-miR-16, anti-NC and treated with CPT for 24 h. (E) HeLa cells transfected with miR-15a, miR-16, Rictor siRNA, or NC were incubated with 10 \(\mu\)M CPT for 36 h. Cells were harvested and stained with PtdIns and annexin V-FITC for apoptotic analysis. (F) The percentage of apoptotic cells were the sum of the early apoptotic cells located in the lower right quadrant (annexin V–FITC –/PI - cells), as well as late apoptotic cells located in the upper right quadrant (annexin V–FITC +/PtdIns - cells). Data shown are means ± SD of three independent experiments, \(*P < 0.05\), **P < 0.01, student 2-tailed t test.
A small RNA with a random sequence was used as a negative control (NC). For transfection, HeLa cells were suspended transfected with Lipofectamine 2000 (Invitrogen, 11668–019), according to the manufacturer’s protocol, 100 pmol siRNA or miRNA was added to each well of a 6-well plate.

**RNA isolation and quantitative RT-PCR**

Total RNA was isolated using RNaseq Plus (Takara, D9108B) according to the manufacturer’s instructions. QRT-PCRs of mRNAs were performed using a reverse transcription kit (Takara, D6130) and SYBR Green Real-time PCR Master Mix (Toyobo, QPK-201). QRT-PCRs of miRNAs were performed according to the manufacturer’s instructions using a TaqMan™ MicroRNA Reverse Transcription Kit (ABI, 4366597) and Real-time PCR Master Mix (Toyobo, QPK-101). MiRNA probes were purchased from ABI: has-miR-15a: (ABI, 000390), has-miR-16 (ABI, 000391), RNU6 (ABI, 001093). MRNA and miRNA expression levels were normalized to GAPDH and RNU6 respectively.

**Luciferase activity assay**

The 3’ UTRs of RICTOR containing either wild type (WT) or mutated (MUT) miR-15a or miR-16 binding sites were inserted into pmirGLO Dual-Luciferase miRNA Target Expression Vectors (Promega, E1330). For luciferase activity assays, HeLa cell were co-transfected with WT or MUT UTR luciferase vectors and miRNAs using lipofectamine 2000 in 24-well plates. About 30h later, Luciferase activity was measured by Dual-Luciferase Reporter assay system (Promega, E1980) and normalized. Each experiment was repeated in triplicate.

**Western blotting**

HeLa cells were lysed with an ice-cold cell extract buffer (50mM Tris-HCl pH8.0, 4M Urea and 1% Triton X-100), containing a protease inhibitor cocktail (Roche, 04693132001). Total protein was equalized and separated by SDS-PAGE and then analyzed by western blotting. Primary antibodies used in this paper were as follows: SQSTM1 (MBL, PM045), LC3B (Sigma, L7543), GAPDH (Proteintech, 10494–1-AP), RICTOR (CST, 2114), phospho-MTOR (Ser2448) (CST, 5536), MTOR (CST, 2972), RPS6KB2/p70S6K (CST, 2708), phospho-RPS6KB2/p70S6K (Thr389) (CST, 9205), Cleaved PARP1 (CST, 5625), Cleaved Caspase-3 (CST, 9661). After incubation with horseradish peroxidase-coupled secondary anti-rabbit antibodies (KPL, 474–1506), protein bands were detected with ECL blotting detection reagents (KPL, 547100).

**GFP-LC3 puncta assay**

Hela GFP-LC3 stable cell were tansfected with miRNAs or anti-miRNAs. Two days after transfection, cells were fixed in 4% paraformaldehyde. GFP-LC3 puncta formation was determined by capturing images using an Olympus FV1000 confocal microscope (Olympus, Japan). The average number of GFP-LC3 dots per cell was counted from at least 200 cells.

**Flow cytometry analysis for cell cycle and apoptosis**

Cells were transfected with miRNA and/or treated with Campothecin (CPT, KeyGen, KGA8152) or Hydroxyurea (HU, Sigma, H8627). For cell cycle distribution assays, the cells were collected and fixed in 70% ethanol in PBS overnight and counter-stained with propidium iodide (PI, Sigma, P4170) and analyzed for DNA content with a BD Influx™ (BD Biosciences) flow cytometer. For apoptosis analysis, cells were trypsinized, washed with PBS 3 times and stained for 15 min in the dark with PI and Annexin V (BD, 556547) at room temperature.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Funding**

This work was supported by National Natural Science Foundation of China (No. 31371315). The International Cooperation Grant of Shenzhen (GJHZ20140416153718941) and the Shenzhen Peacock Program (KQC201109050084A). The China Postdoctoral Science Foundation Funded Project (No. 2014T70070)

---

**References**

1. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j.cell.2011.10.026
2. Mizushima N. The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 2005; 12(Suppl 2):1535-41; PMID:16247501; http://dx.doi.org/10.1038/sj.cdd.4401728
3. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Kitamura A, Oneyama C, Okada M. The mTOR pathway controls cell proliferation by regulating the FoxO3a-mediated transcription factor via SK2 kinase. PloS One 2014; 9:e88891; PMID:24558442; http://dx.doi.org/10.1371/journal.pone.0088891
4. Mirzi S, Nadra S, Kimura H, Tajima S, Takahashi Y, Kitamura A, Oneyama C, Okada M. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factors via SK2 kinase. Proc Natl Acad Sci USA 2012; 109:20061-6; PMID:23015982; http://dx.doi.org/10.1073/pnas.1113880109
5. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Regulation of the Ulk1-Atg13-FIP200 autophagy regulatory complex. Sci Signal 2012; 5:ra41; PMID:23074478; http://dx.doi.org/10.1126/scisignal.2003643
6. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huyhn T, Ferron M, Karsenty G, Vellard MC, et al. A lysosome-to-nucleus signaling mechanism senses and regulates the lysosome. EMBO J 2012; 31:1095-108; PMID:22343943; http://dx.doi.org/10.1038/emboj.2012.32
7. Mah LY, Ryan KM. Autophagy and cancer. Cold Spring Harb Perspect Biol 2012; 4:a008821; PMID:22166310; http://dx.doi.org/10.1101/cshperspect.a008821
8. Scazzosi DF, Guerin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148
9. Mammucari C, Milan G, Raimondo V, Masiello A, Rudolf R, Del Piccolo P, Burden SJ, Di Lisi R, Sandri C, Zhao J, et al. FoxO4 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6:472-83; PMID:17854315; http://dx.doi.org/10.1016/j.cmet.2007.11.001
10. Zhao J, Brulet J, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO4 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6:472-83; PMID:17854315; http://dx.doi.org/10.1016/j.cmet.2007.11.004

---

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Funding**

This work was supported by National Natural Science Foundation of China (No. 31371315). The International Cooperation Grant of Shenzhen (GJHZ20140416153718941) and the Shenzhen Peacock Program (KQC201109050084A). The China Postdoctoral Science Foundation Funded Project (No. 2014T70070)
13. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5; PMID:15372042; http://dx.doi.org/10.1038/nature02871
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002
15. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2009; 8:1960-7; PMID:19609373; http://dx.doi.org/10.4161/cc.8.19.9262
16. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136:215-33; PMID:19609373; http://dx.doi.org/10.1016/j.cell.2009.01.002
17. Dumortier O, Hinault C, Van Obberghen E. Micro-RNAs and metabolism: crosstalk in energy homeostasis. Cell Metab 2013; 18:312-24; PMID:23850135; http://dx.doi.org/10.1016/j.cmet.2013.06.004
18. Krol J, Laedig J, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597-610; PMID:20661255
19. Frankel LB, Lund AH. MicroRNA regulation of microRNAs and metabolism crosstalk in energy homeostasis. Cell Metab 2013; 18:312-24; PMID:23850135; http://dx.doi.org/10.1016/j.cmet.2013.06.004
20. Pourrajab F, Babaei Zarch M, BaghiYazdi M, Hekmat-